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Progress in understanding biological circuits, advances in enabling technologies
including the high-throughput platforms of genomics, proteomics, and metabolomics,
the evolution in drug target discovery, and the development of companion diagnostics
set the healthcare enterprise on the verge of personalized disease management.[1-3]
This revolution in clinical care is dependent on molecular diagnostics that predict and
prevent disease, enabling the diagnosis and treatment of individual patients and
populations.[4-6] Diagnostics biomarkers are quantifiable disease characteristics which
provide information about underlying molecular processes to define disease progression
or predict treatment response.[7]

Familiar diagnostic biomarkers include traditional

measurements (heart rate, blood pressure), imaging techniques (chest X-ray,
mammograms), and protein measurements (PSA, CEA). The revolution in biology and
high-throughput technology has provided an opportunity to develop a new generation of
companion and complementary diagnostics, including single nucleotide polymorphism
(SNP) analysis, genomic and proteomic profiling, epigenetic profiling and gene
expression profiling. In turn, these diagnostics increase disease-specific sensitivity and
specificity contributing to the accuracy of personalized disease management.[2,3,5,6]
This advancing wave of innovation has induced the next generation of biotechnology to
capture the use of companion diagnostics for the application of specific therapeutic
agents to the clinical care of individuals and populations .[8] Yet, as pointed out in this
issue by Milne the potential of biomarker technologies, in the form of companion and
complementary diagnostics, to revolutionize clinical care

has not been fully realized,

reflecting a disconnect between the emergence of discovery technologies and models
for their validation, early adoption and application across disease populations (Milne et
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al).[9,10]

These limiations in the validation of molecular diagnostics has raised

considerations around approval and marketing by regulatory agencies.[4,7,11,12]
Moreover, as highlighted in this issue by Cohen, the paucity of biomarker validation
serves as a considerable obstacle to the adoption of companion diagnostics by
healthcare providers and payors (Cohen). The evolving regulatory and reimbursement
environments, associated with the importance ofanalytic validation and clinical
qualification, has resulted in barriers to adoption that has restricted the full impact of
companion diagnostics in clinical practice.
The emergence of analytic technologies for evaluating nucleic acids and proteins,
associated with the deconvolution of the human genome, provided the technological
“push” to develop molecular biomarkers for disease management.[3-5,7] Conversely,
advances in understanding molecular mechanisms contributing to pathogenesis have
yielded an abundance of drug targets to individualizetherapeutic care, providing the
associated “pull” for development of companion diagnostics.[13] At first, compnaion
diagnostics developed in the model of classical biomarkers, as single elements related
to the response of a patient to a specific therapeutic agent.[14] Their clinical utility was
enhanced by the evolution of rapid next generation nucleic acid sequencing
technologies coupled with mutation-specific PCR supporting high-throughput analyses.
These initial small steps have dramatically expanded to encompass systems-level
dysregulation of complex molecular circuits contributing to pathophysiology.[13-15]
Panels of genetic markers and their disease-specific mutations have been cataloged
and their value in predicting responses to targeted therapeutics is being established.
Beyond genetics, molecular assessment of transcriptomes, SNPs, methylation, and the
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proteome are poised to inform the best therapeutic strategies, as exemplified in this
issue in breast cancer (XYZ).
While companion diagnostics reflect the envisioned future for individualized therapies[15,7], their potential has yet to be realized, reflecting issues of technologies, clincial
validation,

and

mechanisms.[9,10,16]

Unfortuantely,

technologies

supporting

companion diagnostics have not been systematically transitioned from engines of
discovery to diagnostics platforms supporting robust assay performance consistent with
mainstream applications in general clinical laboratories. Similarly, as ponted out by
both Milne and Cohen in this issue, these platforms have not undergone
rigorousanalytic validation, providing defined value for therapeutic management of
disease, in the form of clinical qualification (Milne, Cohen).[4,9,10,16,17]

Further,

diagnostic analytes may be evaluated by different technologies which have not been
cross-validated, reducing cross-platform inter-operability.[4,7,17]

Absence of assay

performance standards with rigorous analytic validation and standardization across
laboratories

and

platforms

contributes

to

diagnostic

irreproducibility.[7,13,17]

Additionally, quantitative and qualitative relationships between analytes and therapeutic
management do not always undergo rigorous clinical qualification, and the evidence
linking a companion diagnsotics with clinical outcomes may not be confusing at best as
highlighted by Cohen (Cohen)[9,10,18,19] The clinical utility of companion diagnostics
should be defined in appropriately powered prospective blinded and randomized clinical
trials, and validated in follow-up trials, to provide unambiguous guidance on the utility of
targeted therapies.[9,10]
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Companion diagnostics influence clinical decision-making which can substantially
impact the economics of patient care.[1,18,19] Indeed, as highlighted in this issue,
companion diagnostics that quantify the expression of Her2 receptors in breast cancer
identify patients who respond to costly monoclonal antibody therapies directed to that
target (XYZ). The profit margins for these companion diagnostics are justified by the
argument that they direct the application of expensive therapeutics selectively to
patients who will benefit in an era of constrained healthcare dollars (Milne, Cohen).
However, the emergence of companion diagnostics specifically, and molecular
biomarkers generally, as high profit products has been one of the engines driving the
boom in biotechnology.[8] Their success depends on whether these products address
robust markets and direct decisions regarding expensive, complex, or dangerous
therapeutic interventions.[8] At stake is a $5 billion market growing at 25% annually.
Historically, the path for developing diagnostics included obtaining approval for
marketing of test kits by the FDA that would then be sold to local clinical
laboratories.[4,18,19] However, molecular diagnostics can forego FDA approval and
achive implementation in central laboratories.[8] Obviating the need for FDA approval
and offering diagnostic tests from a central laboratory, , permits more rapid timelines
and cheaper reduced costs.

However, these higher development efficiencies are

associated with a reciprocal reduction in the pursuit of definitive studies analytically
validating and clinically qualifying diagnostics.[7,9,10,17] It is this paucity of clinical
validation, which creates uncertainties in their value to healthcare economics and to
clinical decision making for therapeutic application, which contributes to restricted
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integration of companion diagnsotics into patient management by payors and
practitioners, respectively.[13,16,17]
As highlighted in this issue, companion diagnostics offer a path from the current empiric
model

of

healthcare

to

the

development

of

deterministic

personalized

medicine.[1,3,5,19] However, the integration of companion diagnostics into practice
management paradigms will only come about with the generation of data that clearly
demonstrates their value proposition for both healthcare economics and clinical
practice. .[7,9,10,16]

In that regard, the development and clinical application of

companion diagnostics should have an established basis of evidence, reflecting clinical
trial design, analytical methodologies, and statistical rigor. Moreover, there may be
benefits in centralizing federal regulatory oversight of approval, marketing, and quality
control in application, in the FDA and/or CMS.[9,11,12] In that context, efforts should be
focused on collaborations across public and private sectors to facilitate the discovery
and application of companion diagnostics that will support the application of
molecularly-targeted therapeutics to achieve a truly personalized approach to
healthcare.[4,7,17-19]
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